Teva Pharmaceutical Industries Current Ratio 2006-2019 | TEVA

Current and historical current ratio for Teva Pharmaceutical Industries (TEVA) from 2006 to 2019. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Teva Pharmaceutical Industries current ratio for the three months ending June 30, 2019 was 0.96.
Teva Pharmaceutical Industries Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2019-06-30 $13.81B $14.45B 0.96
2019-03-31 $13.43B $14.03B 0.96
2018-12-31 $13.79B $14.32B 0.96
2018-09-30 $13.88B $14.83B 0.94
2018-06-30 $14.71B $14.22B 1.04
2018-03-31 $14.69B $14.76B 1.00
2017-12-31 $15.38B $17.92B 0.86
2017-09-30 $16.23B $16.94B 0.96
2017-06-30 $14.60B $15.46B 0.94
2017-03-31 $14.84B $15.90B 0.93
2016-12-31 $17.23B $18.49B 0.93
2016-09-30 $17.39B $19.29B 0.90
2016-06-30 $18.34B $14.41B 1.27
2016-03-31 $16.99B $12.91B 1.32
2015-12-31 $18.40B $13.01B 1.42
2015-09-30 $12.50B $12.98B 0.96
2015-06-30 $13.30B $14.47B 0.92
2015-03-31 $15.71B $12.47B 1.26
2014-12-31 $14.40B $12.29B 1.17
2014-09-30 $13.92B $11.67B 1.19
2014-06-30 $13.55B $11.85B 1.14
2014-03-31 $13.45B $11.40B 1.18
2013-12-31 $13.72B $11.97B 1.15
2013-09-30 $13.91B $12.16B 1.14
2013-06-30 $14.09B $12.84B 1.10
2013-03-31 $14.42B $12.36B 1.17
2012-12-31 $16.36B $12.89B 1.27
2012-09-30 $14.98B $10.63B 1.41
2012-06-30 $14.23B $10.01B 1.42
2012-03-31 $14.97B $13.63B 1.10
2011-12-31 $14.45B $13.68B 1.06
2011-09-30 $13.02B $11.48B 1.13
2011-06-30 $12.60B $10.05B 1.25
2011-03-31 $12.05B $8.89B 1.36
2010-12-31 $12.04B $9.69B 1.24
2010-09-30 $11.86B $9.32B 1.27
2010-06-30 $14.44B $8.18B 1.77
2010-03-31 $12.61B $8.34B 1.51
2009-12-31 $12.14B $7.60B 1.60
2009-09-30 $11.46B $7.23B 1.58
2009-06-30 $11.04B $7.24B 1.52
2009-03-31 $11.14B $8.57B 1.30
2008-12-31 $11.43B $8.48B 1.35
2008-09-30 $10.95B $4.98B 2.20
2008-06-30 $10.82B $5.46B 1.98
2008-03-31 $10.49B $5.75B 1.82
2007-12-31 $9.86B $5.37B 1.84
2007-09-30 $9.13B $5.22B 1.75
2007-06-30 $8.67B $4.74B 1.83
2007-03-31 $8.02B $4.64B 1.73
2006-12-31 $7.64B $4.07B 1.88
2006-09-30 $7.24B $3.94B 1.84
2006-06-30 $6.67B $3.99B 1.67
2006-03-31 $5.86B $3.68B 1.59
2005-12-31 $5.51B $2.26B 2.44
2005-09-30 $4.40B $2.17B 2.03
2005-06-30 $4.26B $2.09B 2.04
2005-03-31 $4.25B $2.19B 1.94
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $7.534B $18.854B
TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $55.467B 10.12
Mylan (MYL) United States $9.750B 4.30
Bausch Health Cos (BHC) Canada $7.256B 4.84
Dr Reddy's Laboratories (RDY) India $6.188B 20.86
ASPEN PHARMACR (APNHY) South Africa $2.891B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.356B 13.26
Amphastar Pharmaceuticals (AMPH) United States $0.934B 45.98
Homology Medicines (FIXX) United States $0.609B 0.00
Voyager Therapeutics (VYGR) United States $0.560B 0.00
Akorn (AKRX) United States $0.492B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.449B 0.00
CymaBay Therapeutics (CBAY) United States $0.311B 0.00
Assembly Biosciences (ASMB) United States $0.224B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.193B 0.26
Zynerba Pharmaceuticals (ZYNE) United States $0.174B 0.00
Sol-Gel Technologies (SLGL) Israel $0.149B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.104B 0.00
Teligent (TLGT) United States $0.041B 0.00